Department of Aging and Geriatric Research, University of Florida, Gainesville, FL, USA.
Department of Biostatistics, University of Florida, Gainesville, FL, USA.
Exp Gerontol. 2020 Mar;131:110821. doi: 10.1016/j.exger.2019.110821. Epub 2019 Dec 28.
Older adults are at high risk of developing cardiovascular disease (CVD). Pre-clinical studies indicate that resveratrol (RSV), a polyphenol commonly found in grapes and red wine, may help prevent development of CVD. Based on our previous reports where the 300 mg and 1000 mg doses appeared safe and improved psychomotor function in a dose-dependent manner, our hypothesis was that RSV would reduce biomarkers of CVD risk in overweight, but otherwise healthy older adults and that 1000 mg would lower CVD biomarkers >300 mg. This analysis was performed on samples from older participants (65 years and older) who were randomized to a 90 day RSV treatment with 300 mg (n = 10), 1000 mg (n = 9) or placebo (n = 10). We measured levels of CVD risk biomarkers i.e. oxidized low-density lipoprotein (oxLDL), soluble E-selectin-1 (sE-selectin), soluble Intercellular Adhesion Molecule-1 (sICAM-1), Soluble Vascular Cell Adhesion Molecule-1 (sVCAM-1), total plasminogen activator inhibitor (tPAI-1). Statistical significance was set at p < 0.05. Both sVCAM-1 and tPAI increased significantly more in the 1000 mg vs. 300 mg and placebo groups. Other biomarkers (300 mg vs. 1000 mg vs. placebo: oxLDL, sEselectin-1 and sICAM-1) followed the same trend toward higher levels in the 1000 mg group compared to the 300 mg and placebo groups, without reaching statistical significance. This pilot project suggests that a higher dose of RSV may increase the levels of CVD risk biomarkers in overweight older adults. Given no change in the CVD risk biomarkers in response to a lower dose, future studies should test the effects of different doses of RSV to evaluate potential detrimental effects of higher doses on CVD biomarkers and measures of cardiovascular function in older adults at risk for CVD.
老年人患心血管疾病 (CVD) 的风险很高。临床前研究表明，白藜芦醇（RSV）是一种常见于葡萄和红酒中的多酚，可能有助于预防 CVD 的发生。基于我们之前的报告，300mg 和 1000mg 剂量似乎是安全的，并以剂量依赖的方式改善了精神运动功能，我们的假设是 RSV 会降低超重但 otherwise 健康的老年人的 CVD 风险生物标志物，并且 1000mg 会降低 CVD 生物标志物 >300mg。这项分析是在随机分配至 90 天 RSV 治疗的老年参与者（65 岁及以上）的样本上进行的，剂量为 300mg（n=10）、1000mg（n=9）或安慰剂（n=10）。我们测量了 CVD 风险生物标志物的水平，即氧化型低密度脂蛋白 (oxLDL)、可溶性 E-选择素-1 (sE-selectin)、可溶性细胞间黏附分子-1 (sICAM-1)、可溶性血管细胞黏附分子-1 (sVCAM-1)、总纤溶酶原激活物抑制剂 (tPAI-1)。统计学意义设定为 p<0.05。与 300mg 和安慰剂组相比，1000mg 组的 sVCAM-1 和 tPAI-1 显著增加。其他生物标志物（300mg 与 1000mg 与安慰剂：oxLDL、sEselectin-1 和 sICAM-1）也呈现出相同的趋势，即 1000mg 组的水平高于 300mg 组和安慰剂组，但未达到统计学意义。这个初步项目表明，较高剂量的 RSV 可能会增加超重老年人的 CVD 风险生物标志物水平。鉴于较低剂量对 CVD 风险生物标志物没有变化，未来的研究应该测试不同剂量的 RSV 的效果，以评估较高剂量对 CVD 生物标志物和 CVD 风险老年人心血管功能测量的潜在有害影响。
